AUROC estimate of four-marker protein panel plus PLCO<sub>m2012</sub> was 0.88 for risk prediction of lung cancer death
Yet, variation in uptake seen by geography, race, smoking history, and age
Black veterans had 34 percent lower odds of screening completion versus White veterans
More patients taking alectinib with low-fat yogurt do not reach the exposure threshold of 435 ng/mL
Lack of significant overall survival advantage seen for indefinite-duration versus fixed-duration immunotherapy
Findings seen compared with stereotactic body radiotherapy for early-stage disease
Improvement seen compared with chemotherapy alone for first-line treatment of advanced non-small cell lung cancer
For ever smokers, log2-transformed years since smoking cessation before diagnosis associated with significantly lower mortality
Integration of definitive local therapy relevant if technically feasible and clinically safe to all disease sites
Benefits seen in terms of pathologic complete response and event-free survival for resectable non-small cell lung cancer